Attgeno announces positive results from Supernitro Phase II study

Today Attgeno AB announces top-line data from their Phase IIa trial, evaluating their new drug Supernitro in patients with pulmonary hypertension. The primary endpoint of the study was achieved, and the results align with continued clinical development. The positive results include a significant and dose-dependent reduction in resistance to blood flow through the pulmonary circulation. No unexpected safety signals were observed. Read More

2024, Jun